Anemia prevalence &
effect on feto-placental axis with treatment with iron, folic acid &
protein powder
Nagar N.1,Mazumdar M.2
1Dr. Nidhi Nagar, Assistant Professor, 2Dr. Mita Mazumdar, Associate
Professor; both authors are affiliated with Department of
Obstetrics and Gynaecology, R.K.D.F. Medical College & Hospital, Bhopal.
Correspondence Author: Dr. Mita Mazumdar, Associate Professor, Department of
Obstetrics and Gynaecology, R.K.D.F. Medical College & Hospital, Bhopal,
India. E-mail: mita1873@gmail.com
Abstract
Aim To find out the specific nutritional deficiency in the
pregnant anaemic mothers and to see the improvement in birth weight and
placental weight with haematinic, folate and antihelminthics. Materials and Methods: Total 111
patients were studied at 24±4 weeks of gestation with a view to know
etio-pathogenesis of anaemia in pregnancy by serum iron, folate and protein
studies. Patients with Hb less than 8.5 g% were given oral haematinics and
protein and followed up to the term. Their maternal cord blood and placentae
were collected at the time of delivery to see the effect of therapy on
foeto-placental axis. Results: Out
of 88 anaemic mothers 85 (96.6%) had either serum iron or folate deficiency or
both. 19.3% patients had pure iron deficiency.Incidence ofpure folate
deficiency was37.5% and 39.8% combined iron and folate deficiency. Control
group with haemoglobin ≥11.0 g% had significant number of women with folate,
iron, or deficiency of both. We have observed significant rise in placental
weight & birth weight of newborn after hematinic & protein therapy. Conclusion: Serum iron, and folate
studies should be done to detect early deficiency ofironand folate as
haemoglobin is not a true indicator of early deficiency. Correction of anaemia
with haematinics and proteins provides a reasonable good indicators of their
deficiency in pregnancy. The severe anaemia was associated with low proteins
and albumin indicating that severe anaemia often coexists with hypoproteinamia
Keywords: Hypoproteinamia, Folate, Feto-palcentalaxis,
Anthelminthic therapy
Author Corrected: 20th February 2019 Accepted for Publication: 24th February 2019
Introduction
A recent I.C.M.R. study has shown
that more than 50 per cent of women have nutritional anaemia in the later
months of pregnancy. For the ultimate control of such widespread anemia, it is
important to isolate the role or each nutrient in its pathogenesis.Fetal programming
occurs when the normal pattern of fetal development is disrupted by an abnormal
stimulus or ‘insult’ applied at a critical point in in utero development. Correction of anaemia with haematinics provides adequate
proof of a nutritional deficiency in its pathogenesis. The effects of anemia on
the foeto-placental axix have been reported to be placental hypertrophy reduced
foetal birth weight, and increased incidence of prematurity and perinatal
mortality. Hypoxia, oxidative and nitrative stress all alter placenta
development and may be a general underlying mechanism that links altered
placental function to fetal programming[1,2].
Anaemia in pregnancy, defined as a
haemoglobin concentration (Hb) < 110 g/L, affects more than 56 million
women globally, two thirds of them being from Asia. Multiple factors lead to anaemia
in pregnancy, nutritional iron deficiency anaemia (IDA) being the commonest.
Underlying inflammatory conditions, physiological haemodilution and several
factors affecting Hb and iron status in pregnancy lead to difficulties in
establishing a definitive diagnosis. IDA is associated with increased maternal
and perinatal morbidity and mortality, and long-term adverse effects in the new
born[3].
Strategies to prevent anaemia in
pregnancy and its adverse effects include treatment of underlying conditions,
iron and folate supplementation given weekly for all menstruating women
including adolescents and daily for women during pregnancy and the post partum
period, and delayed clamping of the umbilical cord at delivery. Oral iron is
preferable to intravenous therapy for treatment of IDA. B12 and folate
deficiencies in pregnancy are rare and may be due to inadequate dietary intake
with the latter being more common. These vitamins play an important role in
embryo genesis and hence any relative deficiencies may result in congenital
abnormalities[4,5].
An attempt has been made in this
study to find out the specific nutritional deficiency in the pregnant anaemic
mothers. It has also been possible to follow a group of mothers by treating
their anaemia at 20-28 weeks gestation and to evaluate the results of such therapy
of comparing the better foeto-placental reserves of iron and folic acid at term
and lesser incidence of prematurity, as against the untreated cases.
Methodology
Type of Study: Prospective
study
Setting: Maternity
unit, Department of Obstetrics & Gynaecology R.K.D.F. Medical
College & Hospital, Bhopal
Inclusion Criteria:Mothers at 24±4 weeks of gestation.
Exclusion
Criteria
a. Subjects
with primary cardiac, renal and hepatic disorder.
b.Women with
history of pathologic blood loss at any stage during pregnancy
One hundred and eleven mothers at
24±4 weeks of gestation were selected from the maternity unit, Department of Obstetrics
& Gynaecology R.K.D.F. Medical College & Hospital, Bhopal. All the women were subjected to investigation from venous
blood as described later. The women selected in these studies were groups as
follows:
Supplemental group: [Group I: The women with haemoglobin level 6 g per cent. Group
2: Hb 6-8.5 gm/dl. Both group I & II were given oral haematinics in
following composition and protein therapy to see the effect or treatment on
Foetoplacetal axis
Test Group: [Group III test]Women between 8.5 to 11 g per/dl were chose for etiopathogenesis
of anaemia in pregnancy.
Control Group: [Group IV control] 23 women with hemoglobin 11.0 g per cent or above served as
control. Oral haematinic was given in form of Ferettes tablets with following
composition. Ferrous Fumerate B.P.,0.25 g Folic acid I.P., 3.0 mg.
Cyanocobalamine I.P. 5 mg. Ascorbic acid I.P.50 mg.These tablets were given one
tablet three times daily after meals. Along with above oral, haematinic tablets,
protein about 15-20 g was also supplemented to each of these patients. These
patients were regularly followed and delivered in the hospital to collect
placenta, cord blood, maternal blood samples. The maternal blood was collected
in first stage of labour.
Clinical history of each mother was
taken and examination was conducted. Care was taken to exclude systemic disease
affecting foetal growth. Stool and urine examinations were also done along with
biochemical estimations mentioned later. The patients with hemoglobin 8.5 g per
cent or less were designated as treated cases and were treated with oral
haematinics and proteins as described. After clinical history and examination,
maternal blood collected for haemoglobin, haematiocrit, transferrin saturation,
serum iron, iron binding capacity, total proteins, albumins and serum folate.
All the patient with hamemoglobin
6.0 g per cent or less were admitted prior to the treatment. They were given
treatment for parasitic infestation if they had, along with oral heamtinics and
proteins. Blood transfusion was also given in some of these patients. All these
patients were discharged after clinical and haematological improvement. All the
patients with haemoglobin 8.5 g per cent or below were regularly followed in
antenatal clinic and were again readmitted at the time of delivery to collect
maternal blood, cord blood and placenta.
Immediately after completion of
second stage of labour about 10 ml. of cord blood was collected without milking
the cord in aheparinized vial. The above-mentioned biochemistry was repeated in
cord blood. As soon as the placenta was delivered, cord was cut close to the
base and the membranes were trimmed off. Adherent blood clots were removed from
the maternal surface of the placenta and sub-choriontic vessels were emptied
off by gentle pressure. The placenta was blotted several times with filter
paper and then it was weighed using the same weighing machine for all the
cases.
Results
Table-1: Haemoglobin, haematocrit and serum protein levels in
different maternal hemoglobin groups
Group |
Range of haemoglobin (g%) |
Haemoglobin (g%) |
Haemotocrit (%) |
Total serum proteins (g%) |
Serum albumin (g%) |
I [supplemental group] |
≤ 6.0 (25) |
4.6 ±0.97 |
13.5 ±2.84 |
4.8 ±0.75 |
2.4 ±0.49 |
II [supplemental group] |
6.1-8.5 (21) |
7.1 ±0.64 |
22.3 ±2.30 |
5.5 ±1.10 |
3.0 ±1.02 |
III [test] |
8.6-10.9 (42) |
9.7 ±0.69 |
29.4 ±2.60 |
5.6 ±1.05 |
3.0 ±1.02 |
IV [control] |
≥11.0 (23) |
12.6 ±0.67 |
36.4 ±2.42 |
5.5 ±0.69 |
2.9 ±0.46 |
Total Observation |
8.7 |
25.9 |
5.4 |
2.9 |
|
111 |
±2.89 |
±8.44 |
±0.97 |
±0.85 |
|
P value |
|||||
I/IV |
|
<0.001 |
<0.001 |
<0.005 |
<0.001 |
II/IV |
|
<0.001 |
<0.001 |
n.s. |
n.s. |
III/IV |
|
<0.001 |
<0.001 |
n.s. |
n.s. |
Correlation Coefficient
|
- |
- |
- |
- |
±0.2385 |
Regression Coefficient
(b) |
- |
- |
- |
- |
+0.0701 |
P value |
- |
- |
- |
- |
<0.02 |
n.s. = not
significant.
Table-2: Maternal serum iron, T.I.B.C., Transferrin
saturation and folate levels indifferent maternal haemoglobin groups (Mean ±
S.D.)
Group |
Range of haemoglobin (g%) |
Serum iron (ug%) |
T.I.B.C. (ug%) |
Transerrin saturation (%) |
Serum folate (ng/ml.) |
I |
≤ 6.0 (25) |
43.6 ±25.12 |
297.0 ±149.73 |
16.6 ±10.85 |
1.6 ±1.02 |
II |
6.1-8.5 (21) |
51.7 ±29.90 |
370.2 ±154.45 |
17.1 ±13.20 |
2.3 ±2.16 |
III |
8.6-10.9 (42) |
62.4 ±29.76 |
327.2 ±142.29 |
23.4 ±13.77 |
4.0 ±3.90 |
IV |
≥11.0 (23) |
82.2 ±21.70 |
196.1 ±80.04 |
46.0 ±15.98 |
3.1 ±2.41 |
Total observations |
60.2 ±30.05 |
297.9 ±140.26 |
24.9 ±17.28 |
3.0 ±2.90 |
|
P value |
|||||
I/IV |
<0.001 |
<0.01 |
<0.001 |
<0.001 |
|
II/IV |
<0.001 |
<0.001 |
<0.001 |
n.s. |
|
III/IV |
<0.01 |
<0.001 |
<0.001 |
n.s. |
|
CorrelationCoefficient
|
+0.4529 |
- |
- |
+0.2092 |
|
RegressionCoefficient
(b) |
+4.7032 |
- |
- |
0.2162 |
|
P value |
<0.001 |
- |
- |
0.05 |
Table-3:
Two way frequency distribution of pregnant women in relation to maternal haemoglobin
and serum albumin levels.
Group |
Haemoglobin (g%) |
No. of
pregnant women |
Serum
albumin |
|||||
<2.25 |
2.25-3.00 |
3.05-3.75>3.75 |
||||||
|
N |
% |
N |
% |
N |
N |
||
I |
≤ 6.0 |
25 |
9 |
36.0 |
15 |
60.0 |
0 |
1 |
II |
6.1-8.5 |
21 |
3 |
14.3 |
12 |
57.1 |
1 |
5 |
III |
8.6-10.9 |
42 |
10 |
23.8 |
18 |
42.9 |
7 |
7 |
IV |
≥ 11.0 |
23 |
0 |
0 |
16 |
69.6 |
6 |
1 |
Total |
111 |
22 |
19.8 |
61 |
54.9 |
14 |
14 |
N=number of pregnant women.
Table-4:
Prevalence of serum iron and serum folate deficiency in different maternal haemoglobin
groups.
Group |
Haemoglobin
(g%) |
Number of
pregnant women |
Serum
iron (ug %) |
Serum
folate (ng/ml) |
Serum
iron <50.0 (ug %)&serum folate <3.0ng/ml |
Serum
iron 50-80ug% Serum
folate ng/ml 3.0-5.9 |
||||||||
<50.0 |
50.0-80.0 |
3.0 |
3.0-5.9 |
|
|
|||||||||
|
|
|
N |
% |
N |
% |
N |
% |
N |
% |
N |
% |
N |
% |
I |
≤6.0 |
25 |
3 |
12.0 |
1 |
4.0 |
7 |
28.0 |
0 |
0 |
13 |
52.2 |
1 |
4.0 |
II |
6.1-8.5 |
20 |
3 |
15.0 |
1 |
5.0 |
6 |
30.0 |
1 |
5.0 |
7 |
35.0 |
2 |
10.0 |
III |
8.6-10.9 |
40 |
8 |
20.0 |
1 |
2.5 |
15 |
37.5 |
4 |
10.0 |
4 |
10.0 |
8 |
20.0 |
IV |
≥ 11.0 |
21 |
0 |
0 |
2 |
9.5 |
6 |
28.6 |
6 |
28.6 |
1 |
4.8 |
6 |
28.6 |
Total |
106 |
14 |
13.2 |
5 |
4.7 |
34 |
32.1 |
11 |
10.4 |
25 |
23.59 |
14 |
13.2 |
Table-5:
Effect of therapy with haematinics and protein on maternal haemoglobin,
haematocrit, serum proteins, iron, and folate levels.
Range of
haemoglobin (g%) |
Group |
Gestation (weeks) |
Haemoglobin (g%) |
Haematocrit (%) |
Total
serum protein (g%) |
Serum
albumin (g%) |
Serum
iron (g%) |
Transferrin
% saturation |
Serum
folate ng/ml |
≤6.0 |
I Anaemic group (12) |
37 ±0.75 |
47 ±0.86 |
13.6 ±2.43 |
4.4 ±0.57 |
2.1 ±0.36 |
43.0 ±14.91 |
14.9 ±4.06 |
0.87 ±0.45 |
|
II
Treatment group (7) |
||||||||
|
a. before treatment |
24.0 ±3.3 |
4.8 ±1.01 |
15.4 ±2.15 |
4.5 ±2.15 |
2.3 ±0.36 |
34.4 ±9.37 |
16.5 ±5.0 |
2.0 ±0.89 |
|
a. after treatment |
38.1 ±1.35 |
10.6 ±2.0 |
31.1 ±6.62 |
5.8 ±0.56 |
3.1 ±0.52 |
55.6 ±23.85 |
31.4 ±16.37 |
2.6 ±1.53 |
|
P values |
|
|
|
|
|
|
|
|
|
I/IIb |
|
<0.001 |
<0.001 |
<0.001 |
<0.005 |
n.s. |
<0.005 |
<0.05 |
|
II/IIb |
|
<0.001 |
<0.001 |
<0.005 |
<0.01 |
<0.05 |
<0.05 |
n.s. |
6.1-8.5 |
I anaemicgroup (15) |
7.1 ±0.76 |
22.0 ±2.83 |
4.6 ±0.57 |
2.3 ±0.29 |
44.5 ±0.29 |
18.8 ±4.12 |
1.5 ±1.12 |
1.5 ±1.12 |
|
II
Treated group (10) |
||||||||
|
a. Before therapy |
23.4 ±2.70 |
7.4 ±0.94 |
22.6 ±2.63 |
4.9 ±0.74 |
2.5 ±0.69 |
46.7 ±27.29 |
15.7 ±7.74 |
2.2 ±1.93 |
|
b. After therapy |
38.4 ±1.46 |
12.1 ±1.72 |
34.4 ±5.76 |
5.8 ±0.83 |
3.2 ±0.75 |
71.8 ±22.31 |
34.5 ±19.39 |
3.3 ±2.65 |
|
P values |
||||||||
|
I/IIb |
|
<0.001 |
<0.001 |
<0.001 |
<0.001 |
<0.005 |
<0.005 |
n.s. |
|
IIa/IIb |
|
<0.001 |
<0.001 |
<0.025 |
n.s. |
<0.05 |
<0.02 |
n.s. |
|
Total
observation |
||||||||
|
I Anamic group (27) |
|
6.1 ±1.46 |
18.3 ±4.99 |
4.5 ±0.57 |
2.3 ±0.33 |
44.5 ±14.97 |
17.1 ±4.46 |
1.2 ±0.9 |
|
II
Treated group (17) |
||||||||
|
a. Before therapy |
23.9 ±2.69 |
6.3 ±1.61 |
19.7 ±4.34 |
4.8 ±0.73 |
2.4 ±0.58 |
41.7 ±22.21 |
16.0 ±6.58 |
2.09 ±1.49 |
|
b. after therapy |
38.3 ±1.36 |
11.5 ±1.92 |
34.2 ±6.49 |
5.8 ±0.71 |
3.1 ±0.64 |
5.1 ±23.69 |
34.2 ±17.73 |
3.07 ±2.31 |
|
P values |
||||||||
|
I/II b |
|
<0.001 |
<0.001 |
<0.001 |
<0.001 |
<0.001 |
<0.001 |
<0.001 |
|
IIa/IIb |
|
<0.001 |
<0.001 |
<0.001 |
<0.005 |
<0.01 |
<0.001 |
n.s. |
The serum iron in mothers with severe, moderate and mild
anaemia were significantly less than those in the mother without anaemia. Out
of 111 patients 34.2% had serum iron below 50.0 ug%. And among the 88 anaemic
patients 84.1% had serum iron below ≤80.0 ug%. The percentage of women with
serum iron less than 50.0 ug% showed a steady decrease with increase in
haemoglobin. Further serum iron was found to have a linear correlation with
maternal haemoglobin levels. Transfer in saturation in mothers with severe
moderate and mild anaemia was significantly less than those in mothers without
anaemia. Out of 111 patients 41.4% had transferrin saturation ≤ 16.0% and among
the 88 anaemic patients 55.3% had transferrin saturation above 16.0 or below,
47.7% had transferrin saturation above 16.0%. The percentage of pregnant women
with transferrin saturation ≤16.0 showed a steady decrease with increase in
serum iron had haemoglobin.
Table-6:
Effect of therapy with hameatinic and proteins on birth weight and placental
tissue
Range of
haemoglobin (g%) |
Group |
Birth
weight (g) |
Placenta |
Placental
coefficient |
|||
Weight
(g) |
Volume
(ml) |
Surface
area |
Number of
cotyledons |
||||
≤6.0 |
I Anaemic group (12) |
2041.7 ±217.38 |
337.5 ±73.22 |
315.0 ±83.72 |
201.1 ±27.73 |
9.7 ±1.73 |
0.168 ±0.036 |
II b treated group (7) |
2916.7 ±334.48 |
420.6 ±62.17 |
422.9 ±100.78 |
290.5 ±86.55 |
14.1 ±86.55 |
0.156 ±0.019 |
|
Change |
+875.0 |
+83.1 |
+107.9 |
+88.4 |
+4.4 |
0.012 |
|
P values |
<0.01 |
<0.02 |
<0.02 |
<0.001 |
<0.001 |
n.s. |
|
6.1-8.5 |
I Anaemic group (15) |
2226.3 ±248.59 |
380.0 ±41.45 |
348.7 ±51.39 |
249.9 ±29.94 |
12.5 ±0.92 |
0.185 ±0.026 |
II b treated group (10) |
3080.6 ±591.78 |
531.8 ±108.85 |
454.0 ±127.0 |
284.9 ±57.19 |
13.1 ±1.79 |
0.16 ±0.031 |
|
Change |
+854.6 |
+151.6 |
+105.3 |
+35.8 |
+0.6 |
0.022 |
|
P values |
<0.001 |
<0.001 |
<0.001 |
n.s. |
n.s. |
n.s. |
|
I/IIb |
|
|
|
|
|
|
|
|
Total
observation |
||||||
|
I (27) Anaemic group |
2032.2 ±253.50 |
361.2 ±60.47 |
337.7 ±68.39 |
221.56 ±27.92 |
11.11 ±1.44 |
0.178 ±0.03 |
|
IIb(17) treated group |
3015.0 ±496.96 |
489.9 ±104.29 |
441.2 ±114.78 |
287.3 ±68.24 |
13.5 ±1.91 |
0.16 ±0.026 |
|
P values |
<0.001 |
<0.001 |
<0.001 |
<0.001 |
<0.001 |
n.s. |
In our study there was significant improvement in the birth
weight in both the groups, the increase being around 40-43 per cent. In
contrast the increase in placental weight 40 percent in the haemoglobin group
6.1-8.5 g per cent as compared to the increase of 25.0 per cent in the
haemoglobin group 6.0 per cent or below it.The placental weight in treated
group (6.1-5.5 g percent) was 531.8 g while the mean placental weight in
haemoglobin group <6.0 g per cent or below was 420.6 g. Although the
difference was 111.2 g this was not statistically significant due to limited
number of observation. The placental volume change in both group were similar.
The number of cotyledons significantly increase in haemoglobin group 6.0 g per
cent or below while no change was observed in the moderate anaemicgroup.In the
low haemoglobin group the gain for birth weight, placental weight, volume,
surface area and number of cotyledons were found to be statistically significant.
The birth weight, placental weight and volume were also significantly increased
with treatment in group 6.1-8.5 g per cent while surface area and number of
cotyledons did not show any significant change. The change in placental co-efficient
in anaemic and treated anaemic group was not found to significant in both the
haemoglobin groups.
Discussion
An
effort has been made to study anaemia in pregnancy by a detailed evaluation of
maternal serum iron, folate and protein contents. The plan was to study the
effect of replacement therapy in at least half the number of cases, where the
treatment could be started at about 20-28 weeks, so that there were about 12-16
weeks for improvement in the foeto-placental axis to occur, if any.
46-
anamic mothers (Hb ≤ 8.5g %) were treated with haematinics, proteins after antihelminthics
for parasites. Only 17 could be followed to term. Their maternal, cord blood
and placental studies were done to assess the effect of treatment on
foeto-placental axis, and their respective values were compared with 27 anaemic
patients delivered in this hospital at term who were not treated for anaemia. 30
anaemic women were primigravida and the rest 58 were multipara. The incidence
of anaemia in primigravida was relatively high, as only 6 of them had history
of chronic diarrhea and 30% had GIT worm infestation. It is likely that these
cases were already anaemic before embarking on pregnancy.
Carriaga MT, Skikne BS et al did their study on serum
transferrin receptor for the detection of iron deficiency in pregnancy. Measurements
of circulating transferring receptor provide a sensitive quantitative index of
tissue iron deficiency in otherwise healthy subjects. This investigation was
undertaken to examine the diagnostic utility of this new iron index in
pregnancy. A battery of iron-related measurements, including serum transferrin
receptor concentrations, was performed on 176 women in third-trimester
pregnancy who were attending a university prenatal clinic. The mean receptor
concentration of 5.96 +/- 2.37 mg/L (+/- 1 SD) did not differ significantly
from concentrations in nonpregnant individuals and the frequency distributions
were likewise comparable. Elevations in serum receptor greater than 8.5 mg/L
occurred only in women with depleted iron stores defined by serum ferritin
concentrations. Abnormal concentrations were found in 11 of 13 women with overt
iron-deficiency anemia.Findings indicate that serum receptor concentrations are
not influenced by pregnancy per se and are a sensitive index of iron
deficiency. By combining serum receptor and serum ferritin measurements, the
entire spectrum of iron status in pregnancy can be assessed [6,7].
Black RE.studied micronutrients in pregnancy
and found thatHb level alone is insufficient to guide management. A complete
work-up (ferritin, transferrin saturation) is essential, preferably with
hematological indices such as hypochromic and microcytic red cells and
reticulocytes, classified by degree of maturity, in particular, before
parenteral therapy is given. Since ferritin acts as both an iron-storage and
acute-phase protein, it cannot be used to evaluate iron status in the presence
of inflammation. A high ferritin level thus requires the presence fo an
inflammatory process to be eliminated before it can be taken at face value[8].
Allen LH studiedAnemia and iron deficiency.
They reviewed current knowledge of the effects of maternal anemia and iron
deficiency on pregnancy outcome. A considerable amount of information remains
to be learned about the benefits of maternal iron supplementation on the health
and iron status of the mother and her child during pregnancy and postpartum..
Mounting evidence indicates that maternal iron deficiency in pregnancy reduces
fetal iron stores, perhaps well into the first year of life. This deserves
further exploration because of the tendency of infants to develop iron
deficiency anemia and because of the documented adverse consequences of this
condition on infant development.The weight of evidence supports the
advisability of routine iron supplementation during pregnancy[9,10,11].
Rohilla M, Raveendran Aetal under
took study to determine the maternal and perinatal outcome in patients with
severe anaemia in pregnancy, with a haemoglobin concentration of <7 g/dl.
The in-hospital data were analysed for 12 months and 2.15% (n = 96) of women were found to have
severe anaemia. Out of these, 18.75% had pre-term premature rupture of
membranes and 5.12% of all deliveries were pre-term. Hypertensive diseases of
pregnancy were seen in 17.7%; abruption in 3.12% and 9.37% had congestive
cardiac failure. Postpartum haemorrhage was seen in 25.5% of the patients and
8.33% had puerperal pyrexia. Fetal distress was seen in 26% of and 33.33% had
small for gestational age neonates; there were 16.66% stillbirths and 4.16%
neonatal deaths. Of the 96 severely anaemic women, six died after admission.
Our study also shows that efforts must be taken towards safe motherhood and
spreading awareness about the various consequences of anaemia, which is usually
preventable with early correction[12].
Sferruzzi-Perri AN, Vaughan OR et al did their work on nutrients
that drive intrauterine growth by providing substrate for tissue accretion,
whereas hormones regulate nutrient distribution between foetal oxidative
metabolism and mass accumulation. By responding to nutrient and oxygen
availability, foetal hormones optimize the survival and growth of the foetus
with respect to its genetic potential, particularly during adverse conditions.
However, changes in the intrauterine growth of individual tissues may alter
their function permanently. In both normal and compromised pregnancies,
intrauterine growth is determined by multiple hormonal and nutritional drivers
which interact to produce a specific pattern of intrauterine development with
potential lifelong consequences for health[13,14].
Conclusion
Out of 88 anaemic
mothers 85 (96.6%) had either serum iron or folate deficiency or both. 19.3%
patients had pure iron deficiency. 37.5% had pure folate deficiency.39.8% had
combined iron and folate deficiency. Control group with haemoglobin ≥11.0 g%
had significant number of women with folate, iron, or both deficiency.
The severe anaemia
was associated with low proteins and albumin indicating that severe anaemia
often coexists with hypoproteinamia. There was marked improvement in birth
weight and placental weight with haematinic and protein therapy of about 14
weeks. The maternal, cord blood and placental haemoglobin showed significant
improvement after therapy.
Funding: No funding required
Conflict of interest: No conflict of interest
Ethical approval: Taken
What this study add to existing knowledge: Correction of anaemia with haematinics and proteins
provides a reasonable good indicators of their deficiency in pregnancy. There
was marked improvement in birth weight and placental weight with haematinic and
protein therapy of about 14 weeks. The maternal, cord blood and placental
haemoglobin showed significant improvement after therapy.
References
1. Agarwal KN, Agarwal DK, Sharma A, Sharma
K. Prevalence of anaemia in pregnant & lactating women in India. Indian
journal of medical research. 2006 Aug 1;124 (2):173.[pubmed]
2. Kaur IP, Kaur S. A comparison of
nutritional profile and prevalence of anemia among rural girls and boys.
Journal of Exercise Science and Physiotherapy. 2011 Jun;7 (1):11.
3. Pathak P, Singh P, Kapil U, Raghuvanshi
RS. Prevalence of iron, vitamin A, and iodine deficiencies amongst adolescent
pregnant mothers. The Indian Journal of Pediatrics. 2003 Apr 1;70 (4):299-301.
4. Pathak P, Kapil U, Kapoor SK, Saxena R,
Kumar A, Gupta N, Dwivedi SN, Singh R, Singh P. Prevalence of multiple
micronutrient deficiencies amongst pregnant women in a rural area of Haryana.
The Indian Journal of Pediatrics. 2004 Nov 1;71(11):1007-14.[pubmed]
5. Myatt L. Placental adaptive responses and
fetal programming. The Journal of physiology. 2006 Apr 1;572(1):25-30.[pubmed]
6. Goonewardene M, Shehata M, Hamad A.
Anaemia in pregnancy. Best practice & research Clinical obstetrics & gynaecology.
2012 Feb 29; 26(1):3-24.[pubmed]
7. Carriaga MT, Skikne BS, Finley B, Cutler
B, Cook JD. Serum transferrin receptor for the detection of iron deficiency in
pregnancy. The American journal of clinical nutrition. 1991 Dec
1;54(6):1077-81.[pubmed]
8. Black RE. Micronutrients in pregnancy.
British Journal of Nutrition. 2001 May 1;85(S2):S193-7.[pubmed]
9. Breymann C. Iron deficiency and anaemia
in pregnancy: modern aspects of diagnosis and therapy. European Journal of
Obstetrics & Gynecology and Reproductive Biology. 2005 Dec 1;123:S3-13.[pubmed]
10. Allen LH. Anemia and iron deficiency:
effects on pregnancy outcome. The American journal of clinical nutrition. 2000
May 1;71(5):1280s-4s.[pubmed]
11. Viveki RG, Halappanavar AB, Viveki PR,
Halki SB, Maled VS, Deshpande PS. Prevalence of anaemia and its epidemiological
determinants in pregnant women. Al Ameen J Med Sci. 2012;5(3):216-3.
12. Rohilla M, Raveendran A, Dhaliwal LK,
Chopra S. Severe anaemia in pregnancy: a tertiary hospital experience from
northern India. Journal of Obstetrics and Gynaecology. 2010 Oct 1;30(7):694-6.[pubmed]
13. Kalaivani K. Prevalence &
consequences of anaemia in pregnancy. Indian J Med Res. 2009 Nov
1;130(5):627-33.[pubmed]
14. Sferruzzi-Perri
AN, Vaughan OR, Forhead AJ, Fowden AL. Hormonal and nutritional drivers of
intrauterine growth. Current Opinion in Clinical Nutrition & Metabolic
Care. 2013 May 1;16(3):298-309.[pubmed]
How to cite this article?
Nagar N, Mazumdar M. Anemia prevalence & effect on feto-placental axis with treatment with iron, folic acid & protein powder. Obg Rev: J obstet Gynecol 2019;5(1):45-52.doi:10. 17511/jobg.2019.i1.09.